Regenerative Medicine Market to Catapult to Over $35 Billion by 2019
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 03/11/13 -- TriMarkPublications.com cites in its newly published " Markets" report that the market will catapult to over $35 billion by 2019. For more information, visit: .
(RM) can be categorized into three main modalities: tissue engineering, biomaterials and biomolecules, e.g., scaffolds, growth factors and stem cell therapy. Tissue-engineered bone products in the orthopedic segment will see steady growth, from $7.5 billion in 2012 to $3.29 billion in 2019. The up-and-coming cardiology and vascular products segment will also see substantial growth, reaching a market value of $3.29 over the forecast period.
The " Markets" report covers:
Tissue-engineered skin, cartilage, bone, peripheral nerves, corneas and blood vessels
Sell culture products
Stem cell transplants
Pluripotent, neural, RPE and limbal stem cells
Cartilage repair
Skin ulcers
Facial reconstruction bone
Tendon, ligament and blood vessel repair
Myocardial patches
Heart valve repair
Kidney repair
Bladder repair
Liver repair
Bioartificial pancreas
The " Markets" report examines companies manufacturing equipment and supplies in the world. Companies covered include: Amorcyte, Ars Arthro, Axiogenesis, AxoGen, Bellicum, BetaStem, Bioheart, Biomet, BioMimetic, BioTissue, Biovest, BrainStorm Cell, California Stem Cell, Cardio3, Cellartis, CellSeed, Cellular, Chromocell, Cognate, Cook, Cytomedix, Cytonet, Cytori, DanDrit, Fibrocell, Forticell, Gamida, Harvest, Histogenics, Humacyte, Integra, Intercytex, iPierian, Japan Tissue Engineering, Kensey Nash, Kiadis, Life Cell, Living Cell, MaxCyte, MediStem, Mesoblast, MolMed, NanoCor, Neuralstem, NeuroNova, NewLink Genetics, Olympus Terumo, OncoMed, Opexa, Organogenesis, Orthovita, Osiris, Osteotech, Pervasis, Pluristem, Proneuronnologies, RegeneRx, ReNeuron, Revivicor, SanBio, Saneron, Sangamo, Stem Cell Authority, StemCells, Stemline, Stratetech, Synthecon, Tengion, Thermogenesis, TiGenics, Tissue Genesis, ViaCyte, Vistagen and Zen-Bio.
Detailed charts with sales forecasts and marketshare data are included. For more information, visit: .
TriMarkPublications.com is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit .
The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.
TriMarkPublications.com
Media Relations
1-888-OK-TRIMARK
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 11.03.2013 - 17:30 Uhr
Sprache: Deutsch
News-ID 238118
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Venture Capital
Diese Pressemitteilung wurde bisher 248 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Regenerative Medicine Market to Catapult to Over $35 Billion by 2019"
steht unter der journalistisch-redaktionellen Verantwortung von
TriMarkPublications.com (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
